title: Immunogenicity and reactogenicity of a reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine in healthy Taiwanese children and adolescents.
abstract: OBJECTIVE
  Disease caused by Bordetella pertussis is increasingly being identified among older children and adults in immunized populations, indicating a waning of the vaccine-induced immunity. These findings suggest the need for booster immunization of older children and adults. Modern acellular reduced-antigen-content vaccines have been developed, which can be given as a booster in individuals more than 4 years of age. This study was to assess the immunogenicity and reactogenicity of Boostrix, GlaxoSmithKline Biologicals' reduced-antigen-content diphtheria-tetanus acellular pertussis (dTpa) vaccine, when administered as a booster in healthy subjects previously primed with DTP vaccine.
  
  
  METHODS
  Healthy Taiwanese children and adolescents aged 6-8 years and 15-20 years, previously primed with DTP vaccine, were enrolled. All received one dose of Boostrix. Two blood samples were taken from each of them, one before vaccination and one at 1 month after vaccination. Serum antibodies to diphtheria and tetanus toxoids and immunoglobulin G (IgG) antibodies against the pertussis components PT, FHA and PRN were measured by enzyme-linked immunosorbent assay (ELISA) technique. Adverse reactions following vaccination were recorded.
  
  
  RESULTS
  A total of 180 subjects were recruited. The vaccine response rates to the pertussis antigens ranged between 89.0-100%. There were no serious adverse events reported during the study period.
  
  
  CONCLUSIONS
  The results of this study suggest that Boostrix may be safely and effectively administered as a booster dose to children previously primed with DTP vaccine.
authors.affiliation: Department of Pediatrics, National Taiwan University Hospital, Taipei, Taiwan.
authors.forename: Li-Min
authors.initials: LM
authors.lastname: Huang
authors.forename: Luan-Yin
authors.initials: LY
authors.lastname: Chang
authors.forename: Haiwen
authors.initials: H
authors.lastname: Tang
authors.forename: Hans L
authors.initials: HL
authors.lastname: Bock
authors.forename: Chun-Yi
authors.initials: CY
authors.lastname: Lu
authors.forename: Fu-Yuan
authors.initials: FY
authors.lastname: Huang
authors.forename: Tzou-Yien
authors.initials: TY
authors.lastname: Lin
authors.forename: Chin-Yun
authors.initials: CY
authors.lastname: Lee
mesh_terms: D000293:Adolescent; D000328:Adult; D000917:Antibody Formation; D000942:Antigens, Bacterial / Q000276:immunology*; D002648:Child; D015721:Diphtheria-Tetanus-Pertussis Vaccine / Q000009:adverse effects* / Q000276:immunology*; D005260:Female; D006801:Humans; D007117:Immunization, Secondary; D007074:Immunoglobulin G / Q000032:analysis; D008297:Male; D013624:Taiwan
chemical_list: D000942:Antigens, Bacterial; C505143:Boostrix; D015721:Diphtheria-Tetanus-Pertussis Vaccine; D007074:Immunoglobulin G